vTv Therapeutics Inc. (VTVT) |
| 31.58 -1.91 (-5.7%) 07-13 16:00 |
| Open: | 33 |
| High: | 33 |
| Low: | 31.33 |
| Volume: | 41,649 |
| Market Cap: | 83(M) |
| PE Ratio: | -33.96 |
| Exchange: | NASDAQ Capital Market |
| Industry: | Biotechnology |
| Sector: | Healthcare |
| Technical analysis | ||||
![]() |
||||
| sell | buy | |||
| Resistance 2: | 38.84 |
| Resistance 1: | 35.62 |
| Pivot price: | 34.87 |
| Support 1: | 30.41 |
| Support 2: | 25.30 |
| 52w High: | 44 |
| 52w Low: | 14 |
vTv Therapeutics Inc. is a biopharmaceutical company in the clinical development stage, primarily focused on creating orally administered treatments, with a significant emphasis on diabetes. Its pipeline features lead candidates such as TTP399, an oral, small-molecule, liver-specific glucokinase activator targeting Type 1 diabetes. Another key investigational drug is HPP737, an oral phosphodiesterase type 4 (PDE4) inhibitor that does not cross the blood-brain barrier (non-CNS penetrant), designed to treat inflammatory conditions and psoriasis. Beyond these, vTv Therapeutics' broader clinical portfolio includes: TTP273, an oral small-molecule GLP-1 receptor agonist addressing postprandial glucose excursions in cystic fibrosis-related diabetes. HPP3033, which employs a non-electrophilic strategy to activate the Nrf2 pathway for chronic conditions linked to oxidative stress. Azeliragon, a RAGE antagonist being evaluated for inflammatory lung disorders, notably severe COVID-19, alongside pancreatic and breast cancers. HPP971, an Nrf2 activator aimed at renal diseases, developed in collaboration with pharmaceutical partners. Furthermore, vTv holds a licensing agreement with Reneo Pharmaceuticals, Inc. for the development and commercialization of its peroxisome proliferation-activated receptor delta agonist program, which features the compound HPP593. The company has also established various other licensing and research collaborations with entities such as Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd., Newsoara Biopharma Co., Ltd., JDRF International, and Novo Nordisk A/S. Established in 2015, vTv Therapeutics is headquartered in High Point, North Carolina, and operates as a subsidiary of MacAndrews & Forbes Incorporated.
| EPS | -0.780 |
| Book Value | 7.250 |
| PEG Ratio | 0.00 |
| Gross Profit | 3.256 |
| Profit Margin (%) | 6.11 |
| Operating Margin (%) | 63.15 |
| Return on Assets (ttm) | -2.9 |
| Return on Equity (ttm) | -1.5 |
Thu, 02 Jul 2026
vTv Therapeutics lures two employees with 12,500 stock options - Stock Titan
Thu, 02 Jul 2026
vTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
Mon, 29 Jun 2026
Price to earnings forward of vTv Therapeutics Inc. – NASDAQ:VTVT - TradingView
Mon, 29 Jun 2026
Director at vTv Therapeutics (VTVT) awarded 6,000 stock options grant - Stock Titan
Mon, 29 Jun 2026
Director at vTv Therapeutics (VTVT) receives 6,000 stock options grant - Stock Titan
Mon, 29 Jun 2026
[8-K] vTv Therapeutics Inc. Reports Material Event - Stock Titan
|
StockChart iOS |
StoxlineLite iOS |
StoxlineLite iOS |
OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |